Navigation Links
Cephalon Reports Another Strong Quarter
Date:10/28/2008

49,672 (281,800) 206,587 (133,273)

INCOME TAX EXPENSE (BENEFIT) (62,371) 24,963 (4,375) 102,613

NET INCOME (LOSS) $112,043 $(306,763) $210,962 $(235,886)

BASIC INCOME (LOSS) PER

COMMON SHARE $1.64 $(4.58) $3.11 $(3.55)

DILUTED INCOME (LOSS) PER

COMMON SHARE $1.42 $(4.58) $2.79 $(3.55)

WEIGHTED AVERAGE NUMBER OF

COMMON SHARES OUTSTANDING 68,118 66,931 67,855 66,398

WEIGHTED AVERAGE NUMBER OF

COMMON SHARES OUTSTANDING-

ASSUMING DILUTION 78,920 66,931 75,580 66,398

CEPHALON, INC. AND SUBSIDIARIES

Reconciliation of GAAP Net Income to Adjusted Net Income

(Unaudited)

Three Months Ended

September 30,

2008 2007

GAAP NET (LOSS) INCOME $112,043 $(306,763)

Cost of sales adjustments 54,569 (1) 22,255 (1)

Research and development adjustments 259 (2) 15,000 (2)

Selling, general and administrative

adjustments 27,169 (3) -

Settlement reserve 7,450 (4) 369,000 (4)

Gain on extinguishment of debt - (5,319) (5)

Interest expense adjustment 3,750 (6)

Restructuring charges 1,497 (7)

Income tax adjustment (113,832) (8) (21,693) (8)

(19,138) 379,243

ADJUSTED NET INCOME $92,905 $72,480

BASIC ADJUSTED INCOME PER COMMON

SHARE $1.36
'/>"/>

SOURCE Cephalon, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19

Related biology technology :

1. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
2. Cephalon, Inc. Announces Agreement to Acquire AMRIX, A Once-Daily Extended-Release Muscle Relaxant
3. Cephalon Reinforces Important Prescribing and Dosing Information for FENTORA
4. Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia
5. Cephalon Quarterly Conference Call Invitation
6. Cephalon Announces Strong Third Quarter Financial Results
7. Cephalon Submits Supplemental New Drug Application for FENTORA
8. Cephalon Submits New Drug Application for TREANDA for the Treatment of Patients with Relapsed Indolent Non-Hodgkins Lymphoma
9. Cephalon Presentation Slides for the 26th Annual JPMorgan Healthcare Conference Now Available
10. Cephalons EFFENTORA Receives Positive Opinion from European Regulatory Authorities for the Management of Breakthrough Cancer Pain
11. Cephalon Provides Update on Regulatory Status of the FENTORA Supplemental New Drug Application
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... October 22, 2014 Grace Century, a ... healthcare projects, announces the addition of Dr. Yousef ... its advisory team. Dr. Siddiqui will provide further healthcare ... A graduate of University College Medical School ... in medicine in 2001. With further certification as a ...
(Date:10/22/2014)...   Synthetic Biologics, Inc. (NYSE MKT: SYN), ... infections and diseases, announced today that the U.S. Patent ... for a composition of matter patent application that covers ... SYN-004. This is Synthetic Biologics, first allowed patent application ... to the Company,s extensive C. difficile patent ...
(Date:10/22/2014)... 22, 2014 Research and Markets  has ... by Material, by Application, Geography - Global Analysis and ... Organic electronics, also called as polymer ... science which deals with small conductive molecules and electrically ... molecules and polymers are carbon based, made using synthetic ...
(Date:10/20/2014)... 2014 Mapp Biopharmaceutical,s valiant effort to ... to fight the Ebola outbreak will make the ... production of pharmaceuticals can be, according to Kalorama ... while some may be taken aback by the ... industry knowledge are well aware of the complex ...
Breaking Biology Technology:Dr. Yousef Siddiqui joins the Grace Century Advisory Team 2Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 2Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 3Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 4Global Organic Electronics (Semiconductor, Conductive, Dielectric and Substrate) Market - Analysis and Forecast (2014 - 2020) 2Global Organic Electronics (Semiconductor, Conductive, Dielectric and Substrate) Market - Analysis and Forecast (2014 - 2020) 3Kalorama: ZMapp Highlights Need For Faster Biopharmaceutical Production 2Kalorama: ZMapp Highlights Need For Faster Biopharmaceutical Production 3
... on powerful computational tools and a state-of-the-art scanning ... Wisconsin-Madison and Iowa State University materials science and ... structure in solid metallic materials known as metallic ... Physical Review Letters , the findings fill ...
... May 11, 2012   Synthetic Biologics, Inc. (NYSE Amex: ... and innovative disease-modifying medicines for serious illnesses, announced today ... Board, it has split the roles of Chairman and ... serve as its independent, non-executive Chairman of the Board. ...
... ORLANDO, Fla., May 10, 2012   GeneLink, Inc. ... leading consumer genomics biotech company, reports financial results for the ... Results: , The Company reached an agreement ... Life Sciences, Inc. to Capsalus Corp (OTCBB:WELL.OB, or "Capsalus"). Capsalus ...
Cached Biology Technology:In metallic glasses, researchers find a few new atomic structures 2In metallic glasses, researchers find a few new atomic structures 3Synthetic Biologics Appoints Jeffrey J. Kraws as Independent Chairman 2Synthetic Biologics Appoints Jeffrey J. Kraws as Independent Chairman 3GeneLink Reports 2011 Financial Results 2GeneLink Reports 2011 Financial Results 3
(Date:10/17/2014)... German . Why ... order to reproduce? And why are there two sexes anyway? ... issue of the research journal Molecular Human Reproduction ... from Bielefeld University Bielefeld has compiled this special issue on ... female to copulate with several males in quick succession – ...
(Date:10/16/2014)... have a new synthesis of recent research findings to ... in the two states. , The Ecology and ... Washington: A Synthesis of the Relevant Biophysical Science and ... published by the U.S. Forest Service,s Pacific Northwest Research ... managers for a synthesis of the large body of ...
(Date:10/16/2014)... 2014 NXT-ID, Inc. (NASDAQ: NXTD ... authentication company focused on the growing mobile commerce market ... Wocket™, the Smart Wallet, at the 13 th ... leading global conference on the intersection of technology and ... Anderson , founder and publisher of the Strategic News ...
Breaking Biology News(10 mins):Sperm wars 2New report synthesizes best available science on management of moist mixed-conifer forests 2NXT-ID Inc. to Present at 13th Annual FiRe Conference 2NXT-ID Inc. to Present at 13th Annual FiRe Conference 3
... racking your brain on a Monday morning to remember where ... those keys, you can thank the hippocampus, a brain region ... that room where your keys were hiding in an unusual ... Biological Studies have helped explain how the brain keeps track ...
... A dysfunction of a certain Calcium channel, the so called ... cause different motor diseases as well as a special type ... Dr. Melanie Mark and Prof. Dr. Stefan Herlitze from the ... of the P/Q-type in the modulatory input neurons of the ...
... compared water quality trends in forested streams across the country ... changes. The study, which draws on decades, worth of ... Rico, underscores the value of long-term data in understanding the ... rivers. It is published in the current issue of the ...
Cached Biology News:The neuroscience of finding your lost keys 2The neuroscience of finding your lost keys 3Dysfunction in cerebellar Calcium channel causes motor disorders and epilepsy 2Study explores long-term water quality trends in near-pristine streams 2
... CultureWell cell culture systems provide an ... for staining and imaging. Each system ... standard optical-quality coverslips in cell culture ... sterile and ready to use. Individual ...
RECOMBINANT EQUINE IL-4 Product Type: Recombinant Protein...
RECOMBINANT EQUINE TNF ALPHA Product Type: Recombinant Protein...
Request Info...
Biology Products: